Results from PN400-301/302 studies presented at American College of Rheumatology Annual Scientific Meeting PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) and POZEN Inc. (NASDAQ:POZN) today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA. The data demonstrated that patients at risk for developing NSAID-associated gastric ulcers taking VIMOVO(TM) (naproxen/esomeprazole magnesium, formerly known as PN 400) experienced significantly fewer endoscopically confirmed gastric ulcers (GU) compared with patients taking enteric-coated (EC) naproxen (500 mg) alone. Data from study PN400-301 showed a 4.1% incidence of GU in patients taking VIMOVO, compared to 23.1% among patients taking EC naproxen (p